Volume 5(2); April

< Previous     Next >

Article Contents

Osong Public Health Res Perspect > Volume 5(2); 2014
Park, Cha, Ko, Hwang, Hong, and Lee: Exposure to Dichlorodiphenyltrichloroethane and the Risk of Breast Cancer: A Systematic Review and Meta-analysis



This study extended and updated a meta-analysis of the association between exposure to dichlorodiphenyltrichloroethane (DDT) and the risk of breast cancer.


We reviewed the published literature on exposure to DDE and breast cancer risk to update a meta-analysis from 2004. The total of 35 studies included 16 hospital-based case–control studies, 11 population-based case–control studies, and 10 nested case–control studies identified through keyword searches in the PubMed and EMBASE databases.


The summary odds ratio (OR) for the identified studies was 1.03 (95% confidence interval 0.95–1.12) and the overall heterogeneity in the OR was observed (I2 = 40.9; p = 0.006). Subgroup meta-analyses indicated no significant association between exposure to DDE and breast cancer risk by the type of design, study years, biological specimen, and geographical region of the study, except from population-based case–control studies with estimated DDE levels in serum published in 1990s.


Existing studies do not support the view that DDE increases the risk of breast cancer in humans. However, further studies incorporating more detailed information on DDT exposure and other potential risk factors for breast cancer are needed.


breast cancer; dichlorodiphenyldichloroethylene; meta-analysis; pesticide exposure; systematic review


Dichlorodiphenyltrichloroethane (DDT) is a synthetic chemical that includes p,p′-dichlorodiphenyltrichloroethane (p,p′-DDT), p,p′-dichlorodiphenyldichloroethylene (p,p′-DDE), and p,p′-dichlorodiphenyldichloroethane (p,p′-DDD or p,p′-TDE). DDE (dichlorodiphenyldichloroethylene) is the main metabolite of DDT, which is rapidly converted into DDE in biological systems [1]. After identifying its insecticidal function, DDT was widely used to prevent malaria and some agricultural pests worldwide. Although the use of DDT was banned in most developed countries in the early 1970s, DDT was still used in some developing countries, such as India, Indonesia, and Mexico, until the 1990s to control the mosquitoes that cause malaria [1,2].
DDT is bioaccumulated in the lipid component of biological systems through the food chain because it is highly lipophilic and is resistant to degradation. Therefore, despite its prohibition in many countries, DDT is still present in the environment and the food chain. DDE in particular has a very long half-life and is of toxicological importance. The half-lives of DDT and DDE in humans have been estimated to be between 6 years and 10 years [3]. The DDT and DDE accumulated in the lipid components, such as adipose tissue, are slowly released into the bloodstream [4]. DDT and its metabolites have been associated with adverse effects including obesity, type 2 diabetes mellitus, and carcinogenicity [5–7]. These chemicals can affect various tissues through mechanisms involving the steroidogenic pathway such as antiandrogenic or estrogenic activity, and receptor-mediated changes in protein synthesis [8–10].
Since DDT and DDE were first reported to be related to breast cancer in 1993 [11], there has been increased attention on the association between exposure to DDT and the risk of breast cancer. Although many epidemiological studies have been conducted to investigate the relationship between DDT exposure and breast cancer risk, there is a large heterogeneity between studies and the findings are not conclusive. Because a meta-analysis study showed no evidence of an association between DDT exposure and breast cancer risk [12], several new epidemiological studies have been published about the relationship between the body burden of DDT and breast cancer risk [13–18].
In the work reported here, we aimed to provide an update of a systematic review and meta-analysis to estimate the association between DDE exposure and the risk of breast cancer based on study characteristics.

Materials and methods

2.1 Study selection

We searched and reviewed the PubMed and EMBASE databases to identify eligible epidemiological studies published in English up to August 2012 using selected common keywords related to DDT exposure and the risk of breast cancer. The reference lists of the identified papers and previous literature reviews were carefully examined for additional studies. The combination of keywords such as DDT, chlorphenotane, dichlorodiphenyldichloroethylene, DDE, p,p′-DDE, 1,1-dichloro-2,2-bis(4 chlorophenyl)ethylene, hydrocarbons, chlorinated, organochlorines, organochlorine pesticides, breast cancer, and breast neoplasm were entered as both medical subject heading (MeSH) terms and text words. The subject of the papers was limited to humans for all databases. We included epidemiological studies that met the following criteria: (1) studies that presented original data from case–control or cohort studies; (2) the outcome of interest was clearly defined as breast cancer; (3) the exposure of interest was DDT or DDT metabolites; and (4) studies that provided measurements with relative risk estimates and 95% confidence intervals (CIs), odds ratios (ORs) and 95% CIs, or values in cells of a 2 × 2 table (e.g., number of cases and controls in exposure categories from which the OR could be calculated). If the data were duplicated or shared in more than one study, only the most recent or more comprehensive study was included in the analysis.

2.2 Data extraction

All studies for which an abstract was present were reviewed and extracted independently by two evaluators (E.S.C. and Y.K.) according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [19]. Disagreements between evaluators about selected studies were resolved by discussion. The following data were extracted from the eligible studies and included in the final analysis: first author's name, publication year, study years, country, study design, number of participants (cases and controls), type of biological specimen, and OR with 95% CIs for association between the exposure of DDT and breast cancer.

2.3 Statistical analysis

Meta-analytic techniques that weight the logarithm of the OR of each study by a function of its variance were used to calculate a summary estimate. Meta-analyses were performed on the total data set and separately for the type of design (hospital-based case–control, population-based case–control, and nested case–control), study years (2000s, 1990s, 1980s, 1970s, and 1960s), biological specimen (serum, plasma, and adipose tissue), and geographical region of the study (North America, Europe, Asia, and South America). A random effect model was used to estimate pooled ORs regarding the potential heterogeneity of the study populations. Statistical heterogeneity between studies was assessed with the Q-statistics and quantified by I2, which measured the percentage of total variation in included studies [20]. Significant heterogeneity was defined as the Q-statistics test p < 0.1 or I2 greater than 50%. We assessed potential publication bias by examining funnel plots and using Egger's test. All the statistical analyses were performed using the Stata 12.0 software (StataCorp, College Station, TX, USA).


The PubMed and EMBASE search yielded 530 papers and 44 papers remained after screening based on the inclusion criteria. On reviewing of the full text of the remaining 44 papers, we identified 35 papers on the exposure to DDE and the risk of breast cancer. Two papers each consisted of two subpopulations and we treated the data of each subgroup as a separate study (Figure 1).
Table 1 gives the details of the 35 studies that were included in the meta-analysis. All were case–control studies and of these 10 were prospective (nested case–control) and 16 were hospital based case–control studies, and 11 were population based case–control studies, which consist of 8160 cases and 9280 controls. Five studies indicated a significant positive association with the risk of breast cancer, whereas no significant association was observed in 32 studies. Twenty-two studies conducted in the USA and Canada, eight in Europe, three in Asia, and four in South America. In most studies, the level of DDE was measured in serum samples.
Overall, there was no significant association between the exposure to DDE and the risk of breast cancer in the meta-analysis of all case–control studies (OR 1.03, 95% CI 0.95–1.12; Figure 2A) and there was some evidence for heterogeneity (p = 0.006, I2 = 40.9). However, no significant publication bias was observed in the selected studies (Begg's funnel plot was symmetric; Egger's test, p for bias = 0.145; Figure 2B).
To resolve the heterogeneity, we performed subgroup meta-analyses by the type of study design, study years, type of biological specimen, and country (Table 2). We found a borderline statistically significant summary OR for population-based case–control studies with 1.19 (95% CI 0.99–1.44), although there was a considerable heterogeneity based on the 11 studies (I2 = 61.3). However, there was no significant association in other subgroup meta-analysis.
Figure 3 shows the subgroup meta-analysis for population-based case-control studies with estimated DDE levels in serum published in 1990s. The OR for this subgroup indicated 1.28 (95% CI 1.00–1.65; Figure 3A), although there was a high heterogeneity (Figure 3B). In other stratified meta-analyses, there was no significant association between exposure to DDE and the risk of breast cancer (data not shown).


We found that there was no significant evidence of an association between the risk of breast cancer and exposure to DDE with recent published literature. Subgroup meta-analyses by the type of design, study years, biological specimen, and geographical region of study also do not support a relationship between exposure to DDE and the risk of breast cancer. However, population-based case–control studies with estimated DDE levels in serum and published in the 1990s showed marginally significant findings, which need further investigation.
Many studies did not report an increased risk, despite the first publication reporting an excess of breast cancer associated with exposure to DDE [11]. Five studies [11,14,18,21,22] among the 35 pooled studies included in our meta-analysis found a positive association between exposure to DDE and the risk of breast cancer. There was moderate heterogeneity among the pooled studies. The inconsistency and heterogeneity of the studies could be explained by potential confounders or modifiers that might affect the relationship between DDE and the risk of breast cancer. One potential explanation for the huge differences in the risk of breast cancer and the moderate heterogeneity among pooled studies is that there is a delayed time between exposure and diagnosis. As DDT can remain in the body for a long period, there is a limitation to identifying accurately the exposure period and levels of exposure.
As DDT crosses the placenta to the fetus and is secreted in breast milk [23], human exposure begins during the early prenatal period and continues during the breastfeeding neonatal period. Evidence for DDE release from fat storage tissue in humans has been provided by breastfeeding studies, which have been found to decrease the risk of breast cancer [24,25]. Exposure during the prenatal and neonatal periods may reduce the distinction between the exposed and unexposed groups and make it harder for such studies to show a true causal association. The age at exposure to chemicals such as DDE is also an important modifier in explaining the relationship between exposure and the risk of disease. Cohn et al [27] reported that DDT was associated with breast cancer only for women potentially exposed at a young age (prior to 14 years of age). Thus the relationship between age at exposure to DDT and breast cancer represents an important area in need of further research.
The other limitation is combined exposure with other chemicals in the natural environment. Many persistent organic pollutants, including DDT, are known or suspected to be endocrine disruptors. However, these chemicals do not all have the same effect; some chemicals have an agonistic role in estrogenic effects, but others have an antagonistic role. Thus current estimations may rule out the possibility that there is a particular hazard from these mixtures or one chemical, whereas exposure to several different chemicals may have a pronounced effect due to their combination.
In summary, our meta-analysis found no evidence that there is an association between exposure to DDE and the risk of breast cancer. Although our results indicate no relationship, there are still several limitations to this study, such as the delay time between exposure and diagnosis, age of exposure, the effect of susceptible populations, and combined exposure with other potential carcinogens. It is particularly important to recommend studying the relationship between DDT and breast cancer based on age of exposure and combined exposure to a number of potential carcinogens.

Conflicts of interest

All contributing authors declare no conflicts of interest.


This research was supported by a grant (12161MFDS767) from Ministry of Food and Drug Safety, Osong, Korea in 2012.


This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


1. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for DDT, DDE, and DDD. 2002 Sep. http://www.atsdr.cdc.gov/toxprofiles/tp35-p.pdf[accessed 13.02.14].

2. Turusov V., Rakitsky V., Tomatis L.. Dichlorodiphenyltrichloroethane (DDT): ubiquity, persistence, and risks. Environ Health Perspect 110(2):2002 Feb;125−128.
3. Wolff M.S.. Half-lives of organochlorines (OCs) in humans [Letter]. Arch Environ Contam Toxicol 36(4):1999 May;504.
4. Lim J.S., Son H.K., Park S.K.. Inverse associations between long-term weight change and serum concentrations of persistent organic pollutants. Int J Obes (Lond) 35(5):2011 May;744−747.
5. Elobeid M.A., Padilla M.A., Brock D.W.. Endocrine disruptors and obesity: an examination of selected persistent organic pollutants in the NHANES 1999–2002 data. Int J Environ Res Public Health 7(7):2010 Jul;2988−3005.
6. Everett C.J., Frithsen I.L., Diaz V.A.. Association of a polychlorinated dibenzo-p-dioxin, a polychlorinated biphenyl, and DDT with diabetes in the 1999–2002 National Health and Nutrition Examination Survey. Environ Res 103(3):2007 Mar;413−418.
7. Beard J.. DDT and human health. Sci Total Environ 355(1–3):2006 Feb;78−89.
8. Kelce W.R., Stone C.R., Laws S.C.. Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature 375(6532):1995 Jun;581−585.
9. Steinmetz R., Young P.C., Caperell-Grant A.. Novel estrogenic action of the pesticide residue beta-hexachlorocyclohexane in human breast cancer cells. Cancer Res 56(23):1996 Dec;5403−5409.

10. Lemaire G., Mnif W., Mauvais P.. Activation of alpha- and beta-estrogen receptors by persistent pesticides in reporter cell lines. Life Sci 79(12):2006 Aug;1160−1169.
11. Wolff M.S., Toniolo P.G., Lee E.W.. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 85(8):1993 Apr;648−652.
12. Lopez-Cervantes M., Torres-Sanchez L., Tobias A.. Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ Health Perspect 112(2):2004 Feb;207−214.
13. Laden F., Collman G., Iwamoto K.. 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst 93(10):2001 May;768−776.
14. Charlier C., Foidart J.M., Pitance F.. Environmental dichlorodiphenyltrichlorethane or hexachlorobenzene exposure and breast cancer: is there a risk? Clin Chem Lab Med 42(2):2004 Feb;222−227.
15. Gammon M.D., Wolff M.S., Neugut A.I.. Environmental toxins and breast cancer on Long Island. II. Organochlorine compound levels in blood. Cancer Epidemiol Biomarkers Prev 11(8):2002 Aug;686−697.

16. Ibarluzea J.J., Fernandez M.F., Santa-Marina L.. Breast cancer risk and the combined effect of environmental estrogens. Cancer Causes Control 15(6):2004 Aug;591−600.
17. Iwasaki M., Inoue M., Sasazuki S.. Plasma organochlorine levels and subsequent risk of breast cancer among Japanese women: a nested case-control study. Sci Total Environ 402(2–3):2008 Sep;176−183.
18. McCready D., Aronson K.J., Chu W.. Breast tissue organochlorine levels and metabolic genotypes in relation to breast cancer risk Canada. Cancer Causes Control 15(4):2004 May;399−418.
19. Stroup D.F., Berlin J.A., Morton S.C.. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2000 Apr;2008−2012.
20. Higgins J.P., Thompson S.G.. Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):2002 Jun;1539−1558.
21. Olaya-Contreras P., Rodriguez-Villamil J., Posso-Valencia H.J.. Organochlorine exposure and breast cancer risk in Colombian women. Cad Saude Publica (14 Suppl 3):1998;125−132.
22. Romieu I., Hernandez-Avila M., Lazcano-Ponce E.. Breast cancer, lactation history, and serum organochlorines. Am J Epidemiol 152(4):2000;363−370.
23. Perera F.P., Rauh V., Whyatt R.M.. A summary of recent findings on birth outcomes and developmental effects of prenatal ETS, PAH, and pesticide exposures. Neurotoxicology 26(4):2005 Aug;573−587.
24. Lopez-Carrillo L., Torres-Sanchez L., Moline J.. Breast-feeding and serum p,p'DDT levels among Mexican women of childbearing age: a pilot study. Environ Res 87(3):2001 Dec;131−135.
25. Bradman A.S., Schwartz J.M., Fenster L.. Factors predicting organochlorine pesticide levels in pregnant Latina women living in a United States agricultural area. J Expos Sci Environ Epidemiol 17(4):2007 Jul;388−399.
26. Aronson K.J., Miller A.B., Woolcott C.G.. Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. Cancer Epidemiol Biomarkers Prev 9(1):2000 Jan;55−63.

27. Cohn B.A., Wolff M.S., Cirillo P.M.. DDT and breast cancer in young women: new data on the significance of age at exposure. Environ Health Perspect 115(10):2007 Oct;1406−1414.
28. Dello Iacovo R., Celentano E., Strollo A.M.. Organochlorines and breast cancer. A study on Neapolitan women. Adv Exp Med Biol 472:1999;57−66.
29. Demers A., Ayotte P., Brisson J.. Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. Cancer Epidemiol Biomarkers Prev 9(2):2000 Feb;161−166.

30. Dorgan J.F., Brock J.W., Rothman N.. Serum organochlorine pesticides and PCBs and breast cancer risk: results from a prospective analysis (USA). Cancer Causes Control 10(1):1999 Feb;1−11.
31. Gatto N.M., Longnecker M.P., Press M.F.. Serum organochlorines and breast cancer: a case-control study among African-American women. Cancer Causes Control 18(1):2007 Feb;29−39.
32. Helzlsouer K.J., Alberg A.J., Huang H.Y.. Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiol Biomarkers Prev 8(6):1999 Jun;525−532.

33. Hoyer A.P., Grandjean P., Jorgensen T.. Organochlorine exposure and risk of breast cancer. Lancet 352(9143):1998 Dec;1816−1820.
34. Hoyer A.P., Jorgensen T., Grandjean P.. Repeated measurements of organochlorine exposure and breast cancer risk (Denmark). Cancer Causes Control 11(2):2000 Feb;177−184.
35. Itoh H., Iwasaki M., Hanaoka T.. Serum organochlorines and breast cancer risk in Japanese women: a case-control study. Cancer Causes Control 20(5):2009 Jul;567−580.
36. Krieger N., Wolff M.S., Hiatt R.A.. Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. J Natl Cancer Inst 86(8):1994 Apr;589−599.
37. Laden F., Hankinson S.E., Wolff M.S.. Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the Nurses' Health Study. Int J Cancer 91(4):2001 Feb;568−574.
38. Liljegren G., Hardell L., Lindström G.. Case-control study on breast cancer and adipose tissue concentrations of congener specific polychlorinated biphenyls, DDE and hexachlorobenzene. Eur J Cancer Prev 7(2):1998 Apr;135−140.

39. Lopez-Carrillo L., Blair A., Lopez-Cervantes M.. Dichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case-control study from Mexico. Cancer Res 57(17):1997 Sep;3728−3732.

40. Mendonca G.A., Eluf-Neto J., Andrada-Serpa M.J.. Organochlorines and breast cancer: a case–control study in Brazil. Int J Cancer 83(5):1999 Nov;596−600.
41. Millikan R., DeVoto E., Duell E.J.. Dichlorodiphenyldichloroethene, polychlorinated biphenyls, and breast cancer among African-American and white women in North Carolina. Cancer Epidemiol Biomarkers Prev 9(11):2000 Nov;1233−1240.

42. Moysich K.B., Ambrosone C.B., Vena J.E.. Environmental organochlorine exposure and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 7(3):1998 Mar;181−188.

43. Pavuk M., Cerhan J.R., Lynch C.F.. Case-control study of PCBs, other organochlorines and breast cancer in Eastern Slovakia. J Expo Anal Environ Epidemiol 13(4):2003 Jun;267−275.
44. Raaschou-Nielsen O., Pavuk M., Leblanc A.. Adipose organochlorine concentrations and risk of breast cancer among postmenopausal Danish women. Cancer Epidemiol Biomarkers Prev 14(1):2005 Jan;67−74.

45. Rubin C.H., Lanier A., Kieszak S.. Breast cancer among Alaska Native women potentially exposed to environmental organochlorine chemicals. Int J Circumpolar Health 65:2006 Feb;18−27.
46. Schecter A., Toniolo P., Dai L.C.. Blood levels of DDT and breast cancer risk among women living in the North of Vietnam. Arch Environ Contam Toxicol 33(4):1997 Nov;453−456.
47. Stellman S.D., Djordjevic M.V., Britton J.A.. Breast cancer risk in relation to adipose concentrations of organochlorine pesticides and polychlorinated biphenyls in Long Island, New York. Cancer Epidemiol Biomarkers Prev 9(11):2000 Nov;1241−1249.

48. van't Veer P., Lobbezoo I.E., Martin-Moreno J.M.. DDT (dicophane) and postmenopausal breast cancer in Europe: case-control study. BMJ 315(7100):1997 Jul;81−85.
49. Wolff M.S., Berkowitz G.S., Brower S.. Organochlorine exposures and breast cancer risk in New York City women. Environ Res 84(2):2000 Oct;151−161.
50. Wolff M.S., Zeleniuch-Jacquotte A., Dubin N.. Risk of breast cancer and organochlorine exposure. Cancer Epidemiol Biomarkers Prev 9(3):2000 Mar;271−277.

51. Zheng T., Holford T.R., Mayne S.T.. DDE and DDT in breast adipose tissue and risk of female breast cancer. Am J Epidemiol 150(5):1999 Sep;453−458.
52. Zheng T., Holford T.R., Mayne S.T.. Risk of female breast cancer associated with serum polychlorinated biphenyls and 1,1-dichloro-2,2'-bis(p-chlorophenyl) ethylene. Cancer Epidemiol Biomarkers Prev 9(2):2000 Feb;167−174.

Figure 1
Process used for literature search.
Figure 2
(A) Odds ratios (ORs) for DDT exposure and breast cancer. (B) Funnel plot of all included studies.
Figure 3
(A) Odds ratios for DDT exposure and breast cancer in population-based case–control studies. (B) Funnel plot of population-based case–control studies.
Table 1
Summary of papers included in the meta-analysis for DDT exposure and breast cancer risk
Author (year) Study years Country Design n (cases/controls) Biological specimen OR (95% CI)
Aronson (2000) [26] 1995–1997 Canada Hospital CC 217/213 Adipose tissue 1.10 (0.78–1.55)
Charlier (2004) [14] 2001–2002 Belgium Population CC 231/290 Serum 2.21 (1.41–3.48)
Cohn (2007) [27] 1959–1967 USA Hospital CC 129/129 Serum 1.29 (0.85–1.96)
Dello Lacovo (1999) [28] 1997–1998 Italy Population CC 170/195 Serum 1.02 (0.68–1.54)
Demers (2000) [29] 1994–1997 Canada Population CC 315/307 Plasma 0.91 (0.70–1.17)
Demers (2000) [29] 1994–1997 Canada Hospital CC 315/219 Plasma 1.01 (0.74–1.39)
Dorgan (1999) [30] 1977–1987 USA Nested CC 105/207 Serum 0.70 (0.47–0.99)
Gammon (2002) [15] 1996–1997 USA Population CC 643/427 Serum 1.20 (0.76–1.90)
Gatto (2007) [31] 1995–1998 USA Population CC 355/327 Serum 1.05 (0.82–1.35)
Helzlsouer (1999) [32] 1974 USA Nested CC 235/235 Serum 0.94 (0.71–1.25)
Helzlsouer (1999) [32] 1989 USA Nested CC 105/105 Serum 0.88 (0.56–1.38)
Hoyer (1998) [33] 1976 Denmark Nested CC 237/469 Serum 0.88 (0.56–1.37)
Hoyer (2000) [34] 1976–1978/1981–1983 Denmark Nested CC 240/477 Serum 1.04 (0.70–1.55)
Ibarluzea (2004) [16] 1996–1998 Spain Hospital CC 198/260 Adipose tissue 1.16 (0.83–1.62)
Itoh (2009) [35] 2001–2005 Japan Population CC 349/349 Serum 0.74 (0.48–1.13)
Iwasaki (2008) [17] 1990–1995 Japan Nested CC 139/278 Plasma 1.23 (0.80–1.90)
Krieger (1994) [36] 1964–1969 USA Nested CC 150/150 Serum 1.31 (0.82–2.09)
Laden (2001) [37] 1989–1990 USA Nested CC 372/372 Plasma 0.79 (0.61–1.01)
Liljegren (1998) [38] 1993–1995 Sweden Hospital CC 43/35 Adipose tissue 0.40 (0.10–1.20)
Lopez-Carrillo (1997) [39] 1994–1996 Mexico Hospital CC 141/141 Serum 0.68 (0.43–1.07)
McCready (2004) [18] 1995–1997 Canada Hospital CC 68/52 Adipose tissue 2.48 (1.08–5.71)
Mendonca (1999) [40] 1995–1996 Brazil Hospital CC 162/331 Serum 1.05 (0.75–1.46)
Millikan (2000) [41] 1993–1996 USA Population CC 748/659 Plasma 1.07 (0.86–1.32)
Moysich (1998) [42] 1986–1991 USA Population CC 154/192 Serum 1.15 (0.74–1.79)
Olaya-Contreras (1998) [21] 1995–1996 Colombia Hospital CC 153/153 Serum 1.56 (1.02–2.39)
Pavuk (2003) [43] 1997–1999 USA Hospital CC 24/85 Serum 1.49 (0.45–4.87)
Raaschou-Nielsen (2005) [44] 1993–1997 Denmark Nested CC 363/363 Adipose tissue 0.87 (0.69–1.10)
Romieu (2000) [22] 1990–1995 Mexico Population CC 120/126 Serum 2.02 (1.14–3.57)
Rubin (2005) [45] 1981–1987 USA Population CC 63/63 Serum 0.97 (0.41–2.32)
Schecter (1997) [46] 1994 Vietnam Hospital CC 21/21 Serum 0.69 (0.23–2.07)
Stellman (2000) [47] 1994–1996 USA Hospital CC 232/323 Adipose tissue 0.94 (0.66–1.33)
van't Veer (1997) [48] 1991–1992 Five European countries Hospital CC 265/341 Adipose tissue 0.75 (0.52–1.08)
Wolff (1993) [11] 1985–1991 USA Population CC 58/171 Serum 2.30 (1.31–4.04)
Wolff (2000) [49] 1994–1996 USA Hospital CC 151/317 Serum 0.86 (0.61–1.22)
Wolff (2000) [50] 1987–1992 USA Nested CC 110/213 Serum 0.83 (0.50–1.37)
Zheng (1999) [51] 1994–1997 USA Hospital CC 304/304 Adipose tissue 1.02 (0.73–1.41)
Zheng (2000) [52] 1995–1997 USA Hospital CC 475/502 Serum 1.01 (0.79–1.28)

CC = case-control study; CI = confidence interval; OR = odds ratio.

Table 2
Meta-analysis of the effect of the exposure to DDT on the risk of breast cancer according to subgroup
Studies included No. of Studies OR 95% CI Heterogeneity
Egger’s test (p for bias)
p-value I2 (%)
Type of study design
 Hospital CC 16 1.02 0.91 to 1.15 0.183 24.0 0.780
 Population CC 11 1.19 0.99 to 1.44 0.004 61.3 0.212
 Nested CC 10 0.90 0.81 to 1.01 0.554 0.0 0.274
Study years
 2000s 2 1.28 0.44 to 3.71 0.001 91.5
 1990s 27 1.03 0.94 to 1.24 0.034 35.9 0.169
 1980s 4 0.87 0.69 to 1.09 0.575 0.0 0.908
 1970s 2 0.92 0.73 to 1.17 0.808 0.0
 1960s 2 1.30 0.95 to 1.77 0.962 0.0
Type of biologic specimen
 Serum 24 1.07 0.93 to 1.11 0.006 47.0 0.365
 Plasma 5 0.97 0.85 to 1.11 0.325 14.1 0.910
 Adipose tissue 8 0.98 0.83 to 1.16 0.141 36.0 0.228
 North America 22 1.01 0.92 to 1.10 0.185 21.0 0.524
 Europe 8 1.02 0.81 to 1.29 0.010 62.0 0.246
 Asia 3 0.92 0.63 to 1.36 0.226 32.8 0.900
 South America 4 1.20 0.78 to 1.83 0.012 72.8 0.707

CC = case–control study; CI = confidence interval; OR = odds ratio.

METRICS Graph View
  • 15 Crossref
  • 22 Scopus
  • 798 View
  • 10 Download

Close layer